Free tool
FAERS Monitor: Jemperli
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761223 or its brand name (Jemperli, Dostarlimab-Gxly). Reports on generic versions are filed under their own applications.
Reports
2,493
Serious
2,141
86% of reports
Hospitalization
965
Death reported
296
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression254
- off label use145
- fatigue133
- rash114
- anaemia98
- arthralgia87
- diarrhoea87
- death84
- neuropathy peripheral82
- thrombocytopenia80
- nausea70
- hypothyroidism66
- product use in unapproved indication64
- pyrexia62
- neutropenia60
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 2 |
| 2019 | 9 |
| 2020 | 40 |
| 2021 | 188 |
| 2022 | 174 |
| 2023 | 171 |
| 2024 | 422 |
| 2025 | 742 |
| 2026 | 745 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,666 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malignant neoplasm progressionSignal | 254 | 21.0 | 18.7 | 4,823 |
| hypothyroidismSignal | 66 | 17.5 | 13.8 | 1,008 |
| neuropathy peripheralSignal | 82 | 7.3 | 5.9 | 439 |
| thrombocytopeniaSignal | 80 | 6.0 | 4.9 | 333 |
| anaemiaSignal | 98 | 4.3 | 3.6 | 250 |
| neutropeniaSignal | 60 | 3.7 | 2.9 | 118 |
| rashSignal | 114 | 2.2 | 1.8 | 76 |
| product use in unapproved indicationSignal | 64 | 2.2 | 1.7 | 40 |
| arthralgia | 87 | 1.8 | 1.4 | 29 |
| pyrexia | 62 | 1.5 | 1.2 | 10 |
| fatigue | 133 | 1.4 | 1.2 | 18 |
| off label use | 145 | 1.4 | 1.2 | 17 |
| diarrhoea | 87 | 1.1 | 0.9 | 1 |
| death | 84 | 0.8 | 0.7 | 3 |
| nausea | 70 | 0.7 | 0.6 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.